药物诱导的运动障碍:使用FDA不良事件报告系统 (FAERS) 从2004年到2024年的不成比例分析
Jingjing Zou1, Chenju Zhan1, Yan Feng1
1Department of Nursing, Mindong Hospital Affiliated to Fujian Medical University, Ningde, China.
PloS one
|October 31, 2025
概括
这项研究使用FAERS数据确定了148种与药物诱导运动障碍 (DIMD) 相关的药物. 关键的危险因素包括年轻的年龄,男性性别和特定药物,如美托克洛普拉米德和阿里皮普拉.
科学领域:
- 药物监督 药物监督 药物监督
- 临床药理学 临床药理学
- 药品安全 药品安全
背景情况:
- 药物诱导的运动障碍 (DIMDs) 是一个重大的临床挑战,相关的风险往往不清楚.
- 美国食品和药物管理局的不良事件报告系统 (FAERS) 数据库是识别潜在药物安全信号的关键资源.
研究的目的:
- 通过不成比例分析识别与DIMD相关的高风险药物.
- 通过敏感性分析探索导致DIMDs的人口和临床风险因素.
主要方法:
- 在FAERS数据 (2004年第一季度 - 2024年第四季度) 上使用了四种不成比例分析方法.
- 进行了单向,LASSO和后勤回归分析,以确定DIMD的风险因素.
主要成果:
- 分析了与DIMD相关的138,081份报告,确定了148种可疑药物.
- DIMDs的独立风险因素包括年龄在33岁以下,男性性别,以及62种特定药物 (例如METOCLOPRAMIDE,ARIPIPRAZOLE,CARBIDOPA,LEVODOPA,RISPERIDONE,QUETIAPINE).
- 开发的模型的预测准确度为0.724 (AUC).
结论:
- 对FAERS数据的不成比例性和敏感性分析成功地确定了可能与DIMDs相关的药物.
- 这些发现为临床医生提供了有价值的见解,使他们在处方确定的药物时谨慎行事,并监测患者是否有运动障碍.
- 结果可以为监管机构提供信息,以便在药物安全性方面做出基于证据的决定.
更多相关视频
06:45Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
3.3K
10:17High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
10.2K
相关概念视频
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Drug Regulation
2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K
Drug Dosing: Geriatric Patients
217
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
217
Therapeutic Drug Monitoring: Affecting Factors
193
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
193
FDA Approved Drugs: Changes to Approved Drugs
237
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
237
Dosage Regimens: Partial Pharmacokinetic Parameters
144
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
144
